Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.34
+3.07 (1.50%)
AAPL  274.10
+7.92 (2.97%)
AMD  210.26
+13.66 (6.95%)
BAC  50.05
-1.02 (-2.01%)
GOOG  310.62
-1.07 (-0.34%)
META  637.67
+0.42 (0.07%)
MSFT  386.80
+2.32 (0.60%)
NVDA  192.45
+0.90 (0.47%)
ORCL  144.96
+3.65 (2.58%)
TSLA  404.40
+4.57 (1.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.